Cyclophosphamide
- PDF / 169,339 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 5 Downloads / 133 Views
1 S
Cyclophosphamide Neutropenia: case report
In a retrospective study of 10 patients (aged 4 months–5 years) with Kawasaki disease who received treatment with cyclophosphamide between January 2006 and December 2019 at a hospital in the USA, one boy [age not stated] was described, who developed severe neutropenia following treatment with cyclophosphamide for coronary artery aneurysms. The boy, who had a history of Kawasaki disease and a history of neutropenia in infancy, developed coronary artery aneurysms. Therefore, he started receiving treatment with IV cyclophosphamide 10 mg/kg. Prior to cyclophosphamide, he was treated with IV immune-globulin. Nine days after the administration of cyclophosphamide, he developed treatment related severe neutropenia with absolute neutrophil count (ANC) of 100/mL3. The severe neutropenia resolved without any intervention. During follow-up examination at 3 months, the boy’s ANC level was noted as normal. Halyabar O, et al. Cyclophosphamide use in treatment of refractory Kawasaki disease: A single center case series of 10 patients and literature review. Arthritis and Rheumatology 72 (Suppl. 1): 240-242, May 2020. Available from: URL: http://doi.org/10.1002/art.41304 [abstract]
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803503029
Reactions 26 Sep 2020 No. 1823
Data Loading...
